Tagged with API

manufacturing The managing director of Ejder Kimya, Pervin Ejder explains how the landscape for API and raw materials suppliers has evolved in Turkey, and how the company has pivoted into more value added and total packaged solutions to accommodate changing market dynamics. As an introduction for our readers, Pervin, can you…

Puerto Rico Enrique Alejandro, Director and Team Leader (Finance) of Pfizer Puerto Rico discusses the pharma company’s manufacturing assets in the country. He stresses the importance of innovation as a key to staying competitive in today’s industry. What products are being manufactured in Pfizer’s Puerto Rico facilities? In Barceloneta, our site produces Active Product…

R&D Andres Matesanz, general manager of ChemSwiss Mexico, shares his views on the Mexican API industry and its regulations as well as his personal ambitions for the company’s future.    You started the operations of ChemSwiss here in Mexico in January 2012. What mission did the headquarters entrust you with? The…

API Indian companies are increasingly interested in tapping into the alluring Mexican and Latin American pharmaceutical markets. The general manager of the API and drug producer discusses the vision behind the establishment of operations in Mexico, the company’s achievements so far and its future plans to consolidate local manufacturing and launch…

innovation Hugo Sigman explains how understanding problems in the same way as opportunities helped his company to become what is today, a successful Argentinian conglomerate where life and science is the backbone of multiple businesses.   Please start by describing the Insud group as it stands today, and where it operates.…

recession Dr. Heitor Costa, Executive Director at Apifarm, Portugal, discusses the country’s economic situation and the presence of international pharmaceutical companies despite the recession. He further discusses the current policy and influence of generics on the pharmaceutical industry, and why he feels investment in Portugal is so crucial at a time…

Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…

Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…

R&D Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry to the global forefront.  Taiwan Supra Integration and Incubation Center (Si2C), was launched in November 2011 with the intention of…

Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…

OtoSim Inc. OtoSim’s CEO Andy Sinclair discusses the current issues surrounding otoscopy diagnosis and the potential of the company’s groundbreaking simulation technology. What was your motivation for getting involved with OtoSim Inc. originally? OtoSim’s inventors submitted an invention disclosure via the Hospital for Sick Children (SickKids) to MaRS Innovation, where I was…

Ernst & Young LLP   Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED tax credit process available in Canada.   What do you see as the biggest challenges of life sciences clients in…